Online citations, reference lists, and bibliographies.
← Back to Search

Efficacy And Tolerance Of An Amphotericin B Lipid (Intralipid) Emulsion In The Treatment Of Candidaemia In Neutropenic Patients.

D. Caillot, O. Casasnovas, E. Solary, P. Chavanet, B. Bonnotte, G. Reny, F. Entezam, J. López, A. Bonnin, H. Guy
Published 1993 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
The efficacy and tolerance of a new amphotericin B lipid emulsion (AmB-IL) in which amphotericin B was diluted in a lipid solution for parenteral nutrition (Intralipid) was assessed in fourteen episodes of candidaemia occurring in neutropenic patients. The strains isolated were Candida krusei (nine cases), Candida albicans (three cases), Candida parapsilosis (one case) and Candida lusitaniae (one case). An AmB-IL was administered at a mean dosage of 1.18 mg/kg/day (range 0.73-1.55) for 22 days (range 6-62). Flucytosine was added to AmB-IL in 12 patients (mean duration 10.6 days). Chills were noted in only 3/306 infusions of AmB-IL. A mild increase of serum creatinine level from 9.3 +/- 3 mg/L (baseline) to 10.9 +/- 3 mg/L (after completion of AmB-IL) and mild decrease of creatinine clearance from 83 +/- 28 mL/min to 56 +/- 21 mL/min were observed. These changes did not correlate with either daily or total dose of AmB-IL or length of therapy. Seven patients were cured and six improved (patients who subsequently died due to nonfungal cause) with AmB-IL. One patient died due to C. krusei pneumonia. In conclusion AmB-IL is a well-tolerated method of amphotericin B administration. It could facilitate the use of amphotericin B without impairing its efficacy for the treatment of candidaemia in neutropenic patients.

This paper is referenced by
Effects of in-vitro activity of miconazole and ketoconazole in phospholipid formulations.
A. de Logu (1997)
Do the new lipid formulations of amphotericin B really work?
C. M. Tang (1997)
Antifungal compounds: controversies, queries and conclusions.
J. Graybill (2000)
Antifungal prophylaxis during neutropenia and immunodeficiency.
O. Lortholary (1997)
Solubilizing poorly soluble antimy cotic agents by emulsification via a solvenent-free process
A. Akkar (2008)
Drug-Induced Acute Renal Failure
G. Kaloyanides (1995)
Experience with liposomal Amphotericin‐B in 60 patients undergoing high‐dose therapy and bone marrow or peripheral blood stem cell transplantation
W. Krueger (1995)
Lack of Nephrotoxicity with the Administration of Amphotericin B in a Lipid Emulsion
T. Smith (1994)
Solid lipid nanoparticles as drug carriers: II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate in mice
H. Heiati (1998)
Candida lusitaniae infections in the era of fluconazole availability.
Jimmy L Hawkins (2003)
Anfotericina B: determinación en diversos fluídos biológicos por cromatografía líquida. Aplicación a estudios farmacocinéticos y de estabilidad química
L. Galera (2000)
SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs.
R. Mueller (2004)
Amphotericin B Formulated in a Lipid Emulsion
J. Cleary (1996)
Lipid‐Based Amphotericin B for the Treatment of Fungal Infections
D. Slain (1999)
The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy.
J. Moreno (1999)
Solid lipid nanoparticles as drug carriers. I. Incorporation and retention of the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate
H. Heiati (1997)
Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity
I. Karimzadeh (2013)
Comparison of conventional and lipid emulsion formulations of amphotericin B: Pharmacokinetics and toxicokinetics in dogs.
J. Nieto (2018)
Efficacy and Toxicity of Amphotericin B Liposomal and Lipid Formulations
J. Rho (1995)
Safety and efficacy of Intralipid emulsions of amphotericin B.
T. M. Sievers (1996)
Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
A. Ayestarán (1996)
Amphotericin B (AMB): Deoxycholate and Lipid Formulations
J. Wingard (2010)
Amphotericin B/emulsion admixture interactions: an approach concerning the reduction of amphotericin B toxicity.
E. S. T. Egito (2002)
Serum pharmacology of amphotericin B applied in lipid emulsions.
V. Heinemann (1997)
A retrospective study on the efficacy and safety of amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients.
D. Torre (1998)
Amphotericin B formulations and drug targeting.
J. Torrado (2008)
Comparison of high‐performance liquid chromatography and bioassay of amphotericin B in serum
J. W. Hülsewede (1994)
Behandeling en profylaxe van gegeneraliseerde mycosen
B. Kullberg (1995)
In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Klebsiella pneumoniae and Enterobacter cloacae with fluoroquinolone resistance-associated amino acid alterations in GyrA and ParC.
T. Deguchi (1997)
Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis.
V. Joly (1996)
Progress in fighting systemic fungal infections in haematological neoplasia
B. D. de Pauw (1997)
Plasma protein adsorption patterns on surfaces of Amphotericin B-containing fat emulsions.
S. Schmidt (2003)
See more
Semantic Scholar Logo Some data provided by SemanticScholar